<DOC>
	<DOCNO>NCT00683930</DOCNO>
	<brief_summary>This study design assess efficacy safety CellCept ( 1 g 1.5 g orally twice daily 52 week ) patient pemphigus vulgaris receive prednisone corticosteroid . During study , patient corticosteroid dose gradually reduce respond treatment . The anticipated time study treatment 12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Assess Effect CellCept ( Mycophenolate Mofetil ) Reduced Corticosteroids Patients With Active Pemphigus Vulgaris ( PV )</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adult patient 18 70 year age Diagnosis mild moderate pemphigus vulgaris within past 12 month , require high dose corticosteroid Female patient pregnant , breastfeeding , lactate Regularly schedule plasma exchange ( PE ) intravenous immunoglobulin ( IVIG ) treatment , PE IVIG treatment within 8 week prior randomization CellCept immunosuppressive therapy , except corticosteroid , exceed 2 week total duration within 8 week prior randomization Use PV therapy note , within 4 week prior randomization Use topical corticosteroid within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>